Cicchetti (Altems): “New therapy for haemophilia A has no impact on NHS”
"Ephmoroctocog alfa (Elocta *), the first recombinant factor VIII with a prolonged half-life for haemophilia A, is an innovative therapy ...
"Ephmoroctocog alfa (Elocta *), the first recombinant factor VIII with a prolonged half-life for haemophilia A, is an innovative therapy ...
"Telemedicine is one of the priorities of the National Health Service for patient associations in the midst of the health ...
Email us: [email protected]